2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Autoimmune Disease Skin Inflammation
  5. Psoriasis

Psoriasis

Psoriasis is a chronic, non-contagious autoimmune skin disorder marked by red, scaly patches that may be itchy or painful, commonly affecting the elbows, knees, scalp, and face. It results from an immune-mediated acceleration of skin cell production, leading to abnormal buildup. The condition can mimic other dermatological diseases, making diagnosis challenging. Flare-ups are triggered by factors such as infections, stress, dry skin, and specific medications. Treatment options include topical creams, systemic medications, and phototherapy. In some individuals, psoriasis progresses to psoriatic arthritis, impacting joints and nails. With a strong genetic predisposition, severe cases can lead to substantial physical, functional, and psychosocial impairment.

References:

Psoriasis (45):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117287
    Deucravacitinib 1609392-27-9 99.93%
    Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
    Deucravacitinib
  • HY-B0573B
    Propranolol 525-66-6 99.91%
    Propranolol is a nonselective and BBB-permeable β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
    Propranolol
  • HY-76711
    Naltrexone 16590-41-3 99.94%
    Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone
  • HY-19749
    PD 151746 181765-30-0
    PD 151746 is a selective calpain-1 inhibitor with an IC50 of 260 nM. PD 151746 binds μ-calpain Ca2+-binding sites, and shows selectivity over cathepsin B, papain, trypsin, thermolysin, and basal calcineurin. PD 151746 reduces Oxidized low-density lipoprotein (oxLDL)-induced cytotoxicity, apoptotic DNA fragmentation, and blocks IL-1α maturation. PD 151746 can be used for the research of atherosclerosis and psoriasis.
    PD 151746
  • HY-155978A
    RDN2150 TFA 99.80%
    RDN2150 TFA is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 TFA inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 TFA can be used for psoriasis-related research.
    RDN2150 TFA
  • HY-183326
    Isosorbide di-(methyl fumarate) 2013542-44-2 99.87%
    Isosorbide di-(methyl fumarate) (IDMF), topical DMF (HY-17363) derivative, is an NRF2/ARE pathway activator. Isosorbide di-(methyl fumarate) downregulates ANCR targets, modulates epithelial differentiation, represses proinflammatory cytokine genes, IL-17A- and TNF-induced keratinocyte genes, psoriatic skin lesion-specific genes, and immune response genes. Isosorbide di-(methyl fumarate) stimulates oxidative stress response gene transcription, reduces erythema and scaling in Imiquimod (HY-B0180)-induced psoriasiform lesions. Isosorbide di-(methyl fumarate) exhibits no genotoxicity or radiation sensitivity in skin fibroblasts, is nonirritating and nonsensitizing in rodent models. Isosorbide di-(methyl fumarate) can be used for the research of psoriasis vulgaris.
    Isosorbide di-(methyl fumarate)
  • HY-P992474
    TAVO101
    TAVO101 is a humanized anti-TSLP antibody with an EC50 of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis.
    TAVO101
  • HY-P10587B
    Icotrokinra (hydrochloride) 99.74%
    Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
    Icotrokinra (hydrochloride)
  • HY-149777
    B3GNT2-IN-1 3033557-95-5 99.56%
    B3GNT2-IN-1 is a β-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2) inhibitor with an IC50 of 0.009 μM. B3GNT2-IN-1 is applicable to research related to rheumatoid arthritis, ankylosing spondylitis and psoriasis.
    B3GNT2-IN-1
  • HY-P99335
    Vunakizumab 1792181-33-9
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.
    Vunakizumab
  • HY-176862A
    TCB-32 hydrochloride 169764-95-8
    TCB-32 (Compound I-1) hydrochloride is a FGFR1 agonist with an EC50 of 0.88  μM. TCB-32 hydrochloride significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK1/2 with excellent thermal stability. TCB-32 hydrochloride can replace bFGF in serum-free cell culture media. TCB-32 hydrochloride can be used for tissue repair and wound healing related diseases like psoriasis and eczema research.
    TCB-32 hydrochloride
  • HY-176862
    TCB-32 352513-86-1
    TCB-32 (Compound I-1) is a FGFR1 agonist with an EC50 of 0.88  μM. TCB-32 significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK1/2 with excellent thermal stability. TCB-32 can replace bFGF in serum-free cell culture media. TCB-32 can be used for tissue repair and wound healing related diseases like psoriasis and eczema research.
    TCB-32
  • HY-153701S
    Envudeucitinibum 2417135-66-9 99.56%
    Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases.
    Envudeucitinibum
  • HY-A0158
    Diflorasone 2557-49-5 99.84%
    Diflorasone is a potent topical anti-inflammatory Corticosteroid. Diflorasone induces vasoconstriction when applied topically. Diflorasone can be used in research related to psoriasis, atopic dermatitis/neurodermatitis.
    Diflorasone
  • HY-13743
    Roquinimex 84088-42-6 99.69%
    Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis.
    Roquinimex
  • HY-124404
    12(R)-HETE 82337-46-0 99.90%
    12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation.
    12(R)-HETE
  • HY-N3388
    Licoisoflavone B 66056-30-2 99.46%
    Licoisoflavone B is an orally active flavonoid found in licorice. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Licoisoflavone B inhiibits superoxide anion generation and superoxide anion-induced lipid peroxidation. Licoisoflavone B binds tightly to Lassa virus nucleoprotein and can be used as a nucleoprotein antagonist of Lassa virus. Licoisoflavone B exhibits anti-mutagenic activity
    against carcinogenic mutagen, by preventing DNA damage. Licoisoflavone B can be used for the research of psoriasis, Lassa fever, inflammation and cancer.
    Licoisoflavone B
  • HY-P99754
    Netakimab 1796570-08-5
    Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab
  • HY-P10587A
    Icotrokinra acetate 99.65%
    Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
    Icotrokinra acetate
  • HY-179537
    CKBA 1786406-66-3
    CKBA, a derivative of AKBA (HY-N0892) is an inhibitor of acetyl-CoA carboxylase 1 (ACC1), with an IC50 of 5.02 μM. CKBA inhibits the differentiation of Th17 cells and has IC50 values of 3.28 μM for mouse cells and 3.61 μM for human cells. CKBA ointment significantly alleviates psoriasis-like inflammation in mice. CKBA can be used for the study of psoriasis.
    CKBA